Key result
Latvian patients receiving cardiac resynchronisation therapy had a significantly higher prevalence of atrial fibrillation compared to patients in other European countries (55.1% vs 40.7%, OR 1.79).
Why the study?
The CRT survey II was conducted to compile real-world data and benchmark national practices in cardiac resynchronisation therapy across European Society of Cardiology member states.
Observational (n=11,088)
Yes
The CRT Survey II reveals that while Latvian CRT recipients generally align with European guidelines, they present with more advanced heart failure symptoms, wider QRS, and higher rates of atrial fibrillation compared to the broader European cohort.
Answers are grounded in this paper and cite their sources.
Signals possible underrepresentation of women in Latvian CRT; leaves open generalizability to other ESC states.
The cardiac resynchronisation therapy (CRT) survey II is a joint initiative between the European Heart Rhythm Association and the Heart Failure Association. It compiles real world data about cardiac resynchronisation therapy in European Society of Cardiology member states. 11 088 patients assigned to implantation of CRT with pacemaker function (CRT-P) or CRT with an incorporated defibrillator (CRT-D) were enrolled in the survey starting 1 October 2015 till 31 December 2016 and for each patient, an electronic case report form (eCRF) was completed. Each participating country had each eCRF data-point benchmarked against the total cohort. In total, 79 patients were included from Latvia. The mean age of patients was 68.1, similar to the total cohort of other ESC member states, and 21.8% of patients were female. Latvian patients compared to other countries more often had permanent atrial fibrillation, NYHA class III and IV, ejection fraction 35 %. CRT-Ds and multipolar lead implantation rates were higher. Peri-procedural complication rates were similarly low in both groups. At discharge, prescribed medication rates were similar but more frequently MRAs, ivabradine and calcium channel blockers were prescribed and slightly less frequently ACE inhibitors/ARBs were prescribed. The CRT survey II is a valuable resource that describes ongoing practice of cardiac resynchronisation therapy around Europe and benchmarking against the total cohort is nationally significant for each participating country.
No takes yet. Share an insight, caveat, or question.
Ventiņa et al. (2020) conducted an observational in Heart failure requiring cardiac resynchronisation therapy (n=11,088). Latvian healthcare setting vs. Other ESC member states was evaluated on Prevalence of atrial fibrillation (OR 1.79, 95% CI 1.14-2.80, p=0.010). Latvian patients receiving cardiac resynchronisation therapy had a significantly higher prevalence of atrial fibrillation compared to patients in other European countries (55.1% vs 40.7%, OR 1.79).
Synapse has enriched 10 related papers. Consider them for comparative context: